In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets

Bianca F. Goemans, Christian M. Zwaan, Amy Harlow, Anne H. Loonen, Brenda E S Gibson, Karel Hählen, Dirk Reinhardt, Ursula Creutzig, Michael Heinrich, Gertjan J L Kaspers

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52 pediatric acute myeloid leukemia (AML) and 36 pediatric acute lymphoblastic leukemia (ALL) samples for in vitro sensitivity to tipifarnib using a total cell-kill assay and compared these results to those obtained with normal bone marrow (N BM) samples (n = 25). AML samples were significantly more sensitive to tipifarnib compared to B-cell precursor ALL (BCP ALL) or N BM samples. Within AML, French-American-British (FAB) M5 samples were most sensitive to tipifarnib. T-cell ALL samples were significantly more sensitive than BCP ALL and N BM samples. In AML there was a marked correlation between tipifarnib resistance and daunorubicin or etoposide resistance, but not to cytarabine or 6-thioguanine. RAS mutations were present in 32% of AML and 18% of ALL samples, but there was no correlation between RAS mutational status and sensitivity to tipifarnib. Future studies are needed to identify biomarkers predictive of tipifarnib sensitivity. In addition, clinical studies, especially in T-cell ALL, seem warranted.

Original languageEnglish (US)
Pages (from-to)3532-3537
Number of pages6
JournalBlood
Volume106
Issue number10
DOIs
StatePublished - Nov 15 2005
Externally publishedYes

Fingerprint

tipifarnib
Leukemia, Monocytic, Acute
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
T-cells
Leukemia
Acute Myeloid Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone
B-Lymphoid Precursor Cells
Bone Marrow
Thioguanine
Daunorubicin
Cytarabine
Biomarkers
Etoposide
Transferases
In Vitro Techniques
Assays
Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Goemans, B. F., Zwaan, C. M., Harlow, A., Loonen, A. H., Gibson, B. E. S., Hählen, K., ... Kaspers, G. J. L. (2005). In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood, 106(10), 3532-3537. https://doi.org/10.1182/blood-2005-04-1640

In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib : Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. / Goemans, Bianca F.; Zwaan, Christian M.; Harlow, Amy; Loonen, Anne H.; Gibson, Brenda E S; Hählen, Karel; Reinhardt, Dirk; Creutzig, Ursula; Heinrich, Michael; Kaspers, Gertjan J L.

In: Blood, Vol. 106, No. 10, 15.11.2005, p. 3532-3537.

Research output: Contribution to journalArticle

Goemans, BF, Zwaan, CM, Harlow, A, Loonen, AH, Gibson, BES, Hählen, K, Reinhardt, D, Creutzig, U, Heinrich, M & Kaspers, GJL 2005, 'In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets', Blood, vol. 106, no. 10, pp. 3532-3537. https://doi.org/10.1182/blood-2005-04-1640
Goemans, Bianca F. ; Zwaan, Christian M. ; Harlow, Amy ; Loonen, Anne H. ; Gibson, Brenda E S ; Hählen, Karel ; Reinhardt, Dirk ; Creutzig, Ursula ; Heinrich, Michael ; Kaspers, Gertjan J L. / In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib : Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. In: Blood. 2005 ; Vol. 106, No. 10. pp. 3532-3537.
@article{1bb9b13ec4884acbac6defc5f277429e,
title = "In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets",
abstract = "Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52 pediatric acute myeloid leukemia (AML) and 36 pediatric acute lymphoblastic leukemia (ALL) samples for in vitro sensitivity to tipifarnib using a total cell-kill assay and compared these results to those obtained with normal bone marrow (N BM) samples (n = 25). AML samples were significantly more sensitive to tipifarnib compared to B-cell precursor ALL (BCP ALL) or N BM samples. Within AML, French-American-British (FAB) M5 samples were most sensitive to tipifarnib. T-cell ALL samples were significantly more sensitive than BCP ALL and N BM samples. In AML there was a marked correlation between tipifarnib resistance and daunorubicin or etoposide resistance, but not to cytarabine or 6-thioguanine. RAS mutations were present in 32{\%} of AML and 18{\%} of ALL samples, but there was no correlation between RAS mutational status and sensitivity to tipifarnib. Future studies are needed to identify biomarkers predictive of tipifarnib sensitivity. In addition, clinical studies, especially in T-cell ALL, seem warranted.",
author = "Goemans, {Bianca F.} and Zwaan, {Christian M.} and Amy Harlow and Loonen, {Anne H.} and Gibson, {Brenda E S} and Karel H{\"a}hlen and Dirk Reinhardt and Ursula Creutzig and Michael Heinrich and Kaspers, {Gertjan J L}",
year = "2005",
month = "11",
day = "15",
doi = "10.1182/blood-2005-04-1640",
language = "English (US)",
volume = "106",
pages = "3532--3537",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib

T2 - Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets

AU - Goemans, Bianca F.

AU - Zwaan, Christian M.

AU - Harlow, Amy

AU - Loonen, Anne H.

AU - Gibson, Brenda E S

AU - Hählen, Karel

AU - Reinhardt, Dirk

AU - Creutzig, Ursula

AU - Heinrich, Michael

AU - Kaspers, Gertjan J L

PY - 2005/11/15

Y1 - 2005/11/15

N2 - Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52 pediatric acute myeloid leukemia (AML) and 36 pediatric acute lymphoblastic leukemia (ALL) samples for in vitro sensitivity to tipifarnib using a total cell-kill assay and compared these results to those obtained with normal bone marrow (N BM) samples (n = 25). AML samples were significantly more sensitive to tipifarnib compared to B-cell precursor ALL (BCP ALL) or N BM samples. Within AML, French-American-British (FAB) M5 samples were most sensitive to tipifarnib. T-cell ALL samples were significantly more sensitive than BCP ALL and N BM samples. In AML there was a marked correlation between tipifarnib resistance and daunorubicin or etoposide resistance, but not to cytarabine or 6-thioguanine. RAS mutations were present in 32% of AML and 18% of ALL samples, but there was no correlation between RAS mutational status and sensitivity to tipifarnib. Future studies are needed to identify biomarkers predictive of tipifarnib sensitivity. In addition, clinical studies, especially in T-cell ALL, seem warranted.

AB - Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52 pediatric acute myeloid leukemia (AML) and 36 pediatric acute lymphoblastic leukemia (ALL) samples for in vitro sensitivity to tipifarnib using a total cell-kill assay and compared these results to those obtained with normal bone marrow (N BM) samples (n = 25). AML samples were significantly more sensitive to tipifarnib compared to B-cell precursor ALL (BCP ALL) or N BM samples. Within AML, French-American-British (FAB) M5 samples were most sensitive to tipifarnib. T-cell ALL samples were significantly more sensitive than BCP ALL and N BM samples. In AML there was a marked correlation between tipifarnib resistance and daunorubicin or etoposide resistance, but not to cytarabine or 6-thioguanine. RAS mutations were present in 32% of AML and 18% of ALL samples, but there was no correlation between RAS mutational status and sensitivity to tipifarnib. Future studies are needed to identify biomarkers predictive of tipifarnib sensitivity. In addition, clinical studies, especially in T-cell ALL, seem warranted.

UR - http://www.scopus.com/inward/record.url?scp=27744475074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744475074&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-04-1640

DO - 10.1182/blood-2005-04-1640

M3 - Article

C2 - 16051737

AN - SCOPUS:27744475074

VL - 106

SP - 3532

EP - 3537

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -